Stereotactic body radiation therapy (SBRT) is a newly developed technique currently in clinical use. SBRT originated from stereotactic radiosurgery (SRS) for intracranial tumors. Since the 1990s, SBRT has been widely used in clinical settings for the treatment of lung cancer. We review the history and current standard techniques. Previous clinical studies of lung cancer showed high local control rates with acceptable toxicities. Past and on-going clinical trials are also reviewed.
History
Stereotactic radiotherapy (SRT) is a highly precise irradiation method developed to maintain a fixed precision within 1-2 mm of intracranial tumors. It is a treatment method that aims to minimize the radiation dose administered to the normal tissues and to increase the radiation administered to the tumor by accurately focusing radiation on the target lesion ('target'). SRT was originally developed for clinical application in the 1960s as a 'gamma knife radiosurgery', which most commonly employed single high-dose radiation, and evolved to the current form following the introduction of linear accelerator (LINAC)-based radiosurgery in 1983. Both techniques were initially developed to treat intracranial brain tumors. Their application to the trunk of the body was initiated in the 1990s. In the USA, the technique is known as stereotactic body radiation therapy (SBRT) or stereotactic ablative external radiotherapy (SABR), while in Europe and Japan it is known as extracranial stereotactic radiotherapy (ESRT) and pin-pointed radiotherapy, respectively. Its first recognized use was by Blomgren et al. (1) of the Karolinska Institute in 1991 and ESRT was implemented first in Japan by Uematsu et al. (2) in 1994. However, the main problem with performing SBRT on tumors of the trunk as opposed to brain tumors is tumor movement caused by body and respiratory movements. Therefore, when performing SBRT on tumors of the trunk, it is extremely important to establish patient fixation, breathing control systems and verification of the irradiation field prior to each treatment.
Procedure
Suitable fixation methods are important to restrain the bodies of patients during treatment. Various vacuum contact-type braces that involve styrofoam in a plastic body frame are currently available for use in SBRT.
In lung tumors, tumor movement during respiration cannot be ignored. Methods that address the respiratory movement of patients can be broadly divided into breath-holding, restricted respiration (abdominal compression) and respiratory gating techniques. Efforts to reduce tumor movement during respiration (internal margin [IM] ) are required.
The breath-holding technique is a simple system in which the patient temporarily suspends his/her breathing following an audible signal (3) .
An alternative to this technique is restricted respiration, in which major movements of the patient's diaphragm are restricted by compressing the upper abdomen using a belt or plate-like brace (4) .
In contrast to these methods, a respiratory gating technique has been developed that synchronizes irradiation with the respiratory phase (mainly the expiratory phase) while the patient breathes freely but periodically. In this frequently used technique, sensors are attached to the thoracic or abdominal wall of the patient, or gold markers are inserted into the tumor (5) and irradiation is performed while sensing the patient's breathing. The most advanced techniques include tumor waiting and tumor tracking techniques (6, 7) . Each method has advantages and disadvantages.
In highly accurate treatment planning, radiation oncologists use computed tomography (CT) images usually taken at 1-3-mm intervals to delineate the contour of the tumor and the organs at risk. In recent years, four-dimensional (4D) CT imaging technology has emerged, which involves placing infrared markers on the body surface to obtain a respiratory signal from the patient. Using this technique, target information such as the maximum intensity projection image for the entire respiratory phase can be obtained. This is an extremely useful technique in SBRT.
Once the target is delineated using reconstructed three-dimensional (3D) images such as Beam's or Room's eye views, the radiation field is determined by combining various factors, including the direction and energy of radiation. Non-coplanar 3D conformal multiport irradiation, static multiple arc radiotherapy (SMART) and volumetric multiple arc therapy (VMAT) are often used to calculate the 3D radiation dose; allowing for non-homogeneity correction is essential, as is correction for the radiation dose due to the frame. A Monte Carlo dose calculation algorithm was recently introduced for clinical use. Attention should be paid to the radiation dose prescription used. In Japan, the isocenter is most often the radiation dose prescription point, while the marginal dose of radiation at 80-90% is often used in Europe and the USA. Recently, the 95% planning target volume (PTV) dose (D95) is more frequently used globally.
Prior to the administration of each dose of irradiation, verification images are created and checked using a high-energy X-ray image, portal image or cone-beam CT to confirm that the correct site is being irradiated. In SBRT in particular, verification, is essential prior to irradiation. The reproducibility of the body position with the simulation film during treatment planning is confirmed. As a result, the administration of irradiation within the usual error range of 2-3 mm is possible through the verification of each result before each treatment. In the Japan Clinical Oncology Group (JCOG) 0403 multicenter collaborative clinical trial, a margin of 5 mm was an essential condition (8) . Furthermore, in order to confirm tumor location before treatment, an increasing number of facilities conduct pretreatment verification using either X-ray equipment attached to image-guided radiation therapy (IGRT) or by CT, with equipment set up in the same room as the radiotherapy equipment.
Clinical results and toxicities

Exposure dose and treatment outcomes
A number of fractionated irradiation techniques have been used, including 12 Gy × 4 fractions per radiation treatment (9), 10-12 Gy × 5-6 fractions per radiation treatment (10), 7.5 Gy × 8 fractions per radiation treatment (11) , and 15 Gy × 3 fractions (12) per radiation treatment. Regardless of the technique, a biologically effective dose (BED) >100 Gy resulted in local control rates of 80-97%, with some variation (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (Table 1 ). In these different fractionated irradiation methods, the radiation dose, total dose and number of fractionations were often extrapolated using a linear quadratic (LQ) model calculation based on α/β values. Fowler et al. (18) demonstrated that the LQ model can be clinically applied with few fractionations and that good localized control can be achieved with BED > 100 Gy. In addition, it is unclear whether the number of radiations in SBRT can ultimately be reduced to one. For radiobiological reasons, fractionated irradiation is advantageous as long as hypoxic fractions exist in the tumor. Fractionated irradiation is also safe for normal tissue recovery. Results reported in the USA, Europe and Japan estimate 3-5 fractionated irradiations to be the optimal number of irradiations, whereas the results of single irradiation were unsatisfactory.
Normal tissue toxicities
In clinical results, the incidence of radiation pneumonitis with symptoms greater than CTCAE-Grade 3 was extremely low compared to that of conventional radiotherapy for Stage III lung cancer. In other words, provided the target is an isolated lung tumor <5 cm in diameter, the irradiated volume of the normal lung is within the permissible range. However, in the subgroup of patients with poor respiratory function, particularly those with underlying interstitial lung disease, there is a risk of fatal radiation pneumonitis (0.5-1.2%); thus, extra care is required (19) . Other complications, such as rib fracture, intercostals neuralgia, pleural effusion, liver dysfunction and brachial plexopathy, are also possible. The JCOG 0403 trial showed a very low rate of complications as far as the dose constraints were maintained (8) .
Furthermore, attention should be paid to serious complications related to central tumors close to the hilar or the mediastinum. Reports of fatal hemoptysis (20, 21) and fatal esophageal ulcers (19) underscore the importance of appropriate attention in cases of central lung cancers where irradiation of the mediastinum (heart/large artery, trachea/bronchi and esophagus) is unavoidable.
Clinical trials
The JCOG 0403 Phase II clinical trial of SBRT for T1N0M0 nonsmall cell lung cancer (NSCLC) multicenter collaborative clinical trial was performed in 15 facilities throughout Japan (8, 22) . The purpose of the trial was to evaluate the efficacy and safety of SBRT for T1N0M0 NSCLC. SBRT was evaluated in both operable and inoperable cases. In cases unfit for standard surgery, the trial assessed whether the current standard therapy with a total dose of 60-70 Gy at 2 Gy per day could be replaced. On the other hand, in cases where surgery was possible but refused, the trial examined whether clinical outcomes equivalent to those of surgery could be achieved. The primary endpoint was the 3-year survival rate, with secondary endpoints including the overall survival rate, the progression-free survival period, the type of recurrence and adverse events. The treatment method comprised a total radiation dose of 48 Gy at 12 Gy per day per fraction, 3-4 times per week for a total of four fractions, with a total treatment period of 4-8 days. The results of the operable (but refused) cases reported in 2010 showed that although the majority of subjects were elderly individuals with a mean age of 79 years, the 3-year survival rate was 76% and the 3-year local control rate (calculated as per the Radiation Therapy Oncology Group [RTOG]) was 86%. There were very few adverse events over Grade 3 (6%). The results of the inoperable cases, also in elderly subjects with a mean age of 78 years, were reported in 2012. The 3-year survival rate was 60%, the 3-year local control rate was 88%, and there were no Grade 5 adverse events.
The JCOG 0702, a Phase I study of SBRT for peripheral T2N0M0 NSCLC, concluded that the recommended dose for T2N0M0 NSCLC with PTV < 100 cc was 55 Gy in four fractions and 50 Gy in four fractions for T2N0M0 with PTV > 100 cc (23, 24) .
The JCOG 1408, a randomized Phase III trial comparing two dose-fractionation SBRT for medically inoperable Stage IA NSCLC or small lesions clinically diagnosed as primary lung cancer, started in 2016 (25) . In this study, 42 and 55 Gy doses will be compared in four fractions at the D95. A total of 750 cases are expected to be accrued.
The results of the RTOG 0236 in the US have been reported (26) . This clinical trial tested 60 Gy in three fractions for the purpose of local control in T1-3N0M0 inoperable lung cancers <5 cm in size. The median observation period was 36 months and there was a high local control rate (within the PTV) of 97.6% at 3 years. However, the % 3-year survival rate was only 55.8% because their population consisted of inoperable patients with T1-2N0M0. There were no Grade 5 adverse events and 4% and 24% of events were Grades 4 and 3, respectively.
The US RTOG 0618 Phase II trial of SBRT in the treatment of patients with operable Stage I/II NSCLC is already closed. Only one case underwent surgery for suspected residual tumor after SBRT. The RTOG 0813, a Phase I/II study of SBRT for early-stage, centrally located, NSCLC in medically inoperable patients, is also closed. This dose escalation study for central hilar lung cancer included mostly 10 Gy × 5 fractions and 11 Gy × 5 fractions. The authors concluded that both regimens were acceptable. The RTOG 0915 randomized Phase II study comparing two SBRT schedules for medically inoperable patients with Stage I peripheral NSCLC compared 12 Gy × 4 fractions against 34 Gy × 1 for peripheral NSCLC, reporting no difference between the two doses (27) . Their results showed no significant difference between regimens.
Randomized controlled studies of surgery and SRT, including the ACOSG/RTOG trial and the STARS trial, were stopped because of low patient accrual. Available data in the pooled analysis of two randomized controlled trials (STARS and ROSEL) showed significant favorable survival of SBRT compared to that surgery, as reported by Chang et al. (28) . Additionally, several studies using propensity score matching showed comparable results between SBRT and surgery (29) (30) (31) .
Future perspectives
Screening and detection of early-stage lung cancer
Recent breakthroughs in CT imaging technology have paved the way for the discovery of ground glass opacity (GGO) early-stage lesions in the lung. Currently, surgery is the only option to obtain a definite diagnosis of these lesions. However, it is not rare for patients with these lesions to be unsuitable for radical surgery because of concurrent lung disease. Further studies are needed to determine the feasibility of surgery and SBRT for GGO lesions that expand during observation (32) .
Centrally located lung cancer
When lung cancer develops near the pulmonary hilum, treatment increases the risk of radiation exposure to key structures such as the central trachea and bronchi, the esophagus, the pulmonary artery and the spinal cord. When the tolerance dose is exceeded in these organs, there is a risk of massive hemorrhage due to ulcers in the trachea or bronchi and peripheral bronchial occlusion (20) . However, there is a report of no complications following a standard high-dose irradiation of 10-15 Gy as far as keeping normal tissue dose constraints (33) . The JROSG10-01 trial demonstrated the safety of 60 Gy in eight fractions for the treatment of centrally located NSCLC as long as the dose constraints were maintained (34) . Recently, ultracentral tumors, in which the tumor is directly attached to main organs such as the trachea, bronchus and esophagus, are considered separately. Clinical trials are underway with the aim of identifying the optimal radiation doses (35) Expanding the indications for locally advanced lung cancer
In advanced-stage lung cancer, the irradiation volume increases, making it difficult to apply SBRT in its current form. However, after 60-70 Gy of 3D irradiation, it may be possible to conduct additional SBRT on the remaining tumor. The factors influencing additional radiation exposure include the volume effect, fractionation effect and total treatment duration. The total radiation dose distribution, including these biological factors, needs to be introduced into future treatment planning.
Significance of histological confirmation
Histological confirmation should be done before treatment options are selected. However, there are several situations in which the histology cannot be confirmed. In these clinical settings, clinical or radiological lung cancer must be defined. In the clinical protocol used in the JCOG1408, the histology of unconfirmed tumors was defined as radiolabeled [11F]-2-fluoro-2-deoxy-D-glucose (FDG) uptake and tumor growth in two consecutive CT series. However, the inclusion criteria of clinical lung cancer may include benign pulmonary nodules.
Surgery vs. SBRT
Several propensity score matching analyses have demonstrated that SBRT may be as effective as surgery in some patients with lung cancer. Miyazaki et al. (29) concluded that the outcomes of surgery and SBRT for elderly patients with early-stage NSCLC were roughly the same. Matsuo et al. (30) reported that the difference in overall survival between sublobar resection and SBRT was insignificant and the cumulative incidence of cause-specific death was comparable between groups. Eba et al. (31) concluded that a randomized controlled study is needed for valid comparison based on the outcomes of the JCOG0403 and JCOG0201 trials. Onishi et al. (36) reported the potential benefits of SBRT in patients with operable NSCLC. In Japan, the JCOG 1408 is underway to define an optimal SBRT dose fractionation. The JCOG 0802 and 0804 are still underway, which aim to identify the optimal surgical procedure. However, future randomized studies are urgently required.
New indications for SBRT
In Japan, SBRT is covered by the public health insurance system and is used for patients with primary lung cancer tumors less than 5 cm in diameter, metastatic lung cancer tumors less than four in number, as well as in primary liver cancer, metastatic liver cancer, prostate cancer and arteriovenous malformation of the spinal cord.
Tekatli et al. (37) evaluated the clinical results of the use of SBRT for NSCLC more than 5 cm. They concluded that SBRT in tumors larger than 5 cm resulted in high local control rates and acceptable survival outcomes, with acceptable comorbidity. Sun et al. (38) reported salvage SBRT for isolated lung recurrence of NSCLC. The combination of SBRT with immunotherapy remains unknown, with limited literature evaluated by Kroeze et al. (39) . In comparison with SBRT and particle therapy, Chi et al. (40) reported no difference in survival between the two groups.
Conclusion
Radiation therapy is currently advancing from 3D to 4D treatment modalities using image-guided radiotherapy (IGRT) techniques. We look forward to the future development and clinical application of high-precision radiotherapy, especially in SBRT.
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